| 申文明,那兴邦.艾迪注射液联合化疗治疗晚期非小细胞肺癌临床疗效及对免疫功能影响[J].浙江中西医结合杂志,2022,32(4): |
| 艾迪注射液联合化疗治疗晚期非小细胞肺癌临床疗效及对免疫功能影响 |
| Clinical effect and effect of Eddie injection combined with chemotherapy for non-small cell lung cancer in advanced stage |
| 投稿时间：2021-08-28 修订日期：2022-01-22 |
| DOI： |
| 中文关键词: 艾迪注射液 非小细胞肺癌 免疫功能 临床疗效 |
| 英文关键词:Aidi injection non-small cell lung cancer immune function clinical efficacy |
| 基金项目: |
|
| 摘要点击次数: 713 |
| 全文下载次数: 6 |
| 中文摘要: |
| 【摘 要】 目的：探讨艾迪注射液联合化疗对晚期非小细胞肺癌肺癌临床疗效、免疫功能及安全性研究。方法：选取我院收治120例患者，随机分为对照组60例，观察组60例。对照组给予多西他赛和顺铂。观察组在此基础上给予艾迪注射液50 ml，1次/d，治疗21 d。采用流式细胞仪测定治疗前后T细胞亚群（CD3+、CD4+、CD8+细胞率，以及CD4+/CD8+）变化。采用酶联免疫吸附法（ELISA）测定血清中基质金属蛋白酶（MMP-9）、组织蛋白酶抑制剂-1（TIMP-1）、血管内皮生长因子（VEGF）、肿瘤坏死因子-α（TNF-α）水平，采用透射免疫比浊法测定C-反应蛋白（CRP）含量。并评价两组患者在治疗中近期临床疗效，生活质量及不良反应。结果：对比两组患者一般资料（性别、年龄、病程等）无统计学差异（P＞0.05）。近期疗效比较：与对照组总有效率43.33%（26/60），观察组总有效率为51.67%（28/60）（X2=0.65，P=0.038）；外周血T细胞亚群：与对照组相比，观察组CD8+水平明显升高（X2 = 4.786，P = 0.013），CD4+/ CD8+比例明显降低（X2 = 5.320，P = 0.017）。两组患者生存质量评分，观察组治疗后（79.1±8.3）与对照组（72.1±6.2）相比明显升高（X2 = 1.301，P = 0.015）。治疗后与对照组相比，观察组VEGF、MMP-9、TIMP-1水平也明显降低（P＜0.05）；TNF-α和CRP水平也明显降低。不良反应发生方面，观察组在骨髓抑制、贫血，肝肾功能损伤，乏力发生率明显低于对照组（P＜0.05）。结论：艾迪注射液联合化疗能显著提高晚期非小细胞肺癌患者的疗效，提高患者免疫力，改善生存质量，降低化疗药物毒副作用，且安全性高，值得临床推荐作为治疗非小细胞肺癌的综合治疗手段之一。 |
| 英文摘要: |
| [Abstract] Objective: To investigate the clinical efficacy, immune function and safety of Eddie injection combined with chemotherapy on advanced NSCLC lung cancer. Methods: 120 patients were admitted in our hospital, 60 randomly divided into the control group and 60 in the observation group. The control group was given docetaxel and cisplatin. The observation group received 21 d. with 50 ml, 1 / d, Changes in T cell subsets (CD3+, CD4+, CD8+ cell rates, and CD4+/CD8+) before and after treatment were determined by flow cytometry. The levels of matrix metalloproteinase (MMP-9), cathepsin inhibitor-1 (TIMP-1), vascular endothelial growth factor (VEGF), tumour necrosis factor- α were determined in the serum assay by enzyme-linked immunosorbent assay (ELISA), and C-reactive protein (CRP) content was determined by transmission immunopacturbidity assay. The recent clinical efficacy, quality of life and adverse effects in the two groups were also evaluated. Results: No general data (gender, age, disease course, etc.) were compared between the two groups (P> 0.05). Recent efficacy comparison: 43.33% (26/60), 51.67% (28/60) (X2=0.65, P=0.038), peripheral blood T cell subset: X2 = 4.786, P = 0.013) and CD4+/CD8+ ratio (X2 = 5.320, P = 0.017). Patient quality of survival score in both groups was significantly increased after treatment (79.1 ± 8.3) compared to control (72.1 ± 6.2) (X2 = 1.301, P = 0.015). VEGF, MMP-9, TIMP-1 levels were also significantly reduced in the observed group after treatment as compared to controls (P<0.05); TNF-α and CRP levels were also significantly reduced.In terms of adverse reactions, the observed group was significantly lower in myelosuppression, anemia, liver and kidney function impairment, and fatigue incidence than in the control group (P<0.05). Conclusion: Eddie injection combined with chemotherapy can significantly improve the efficacy of patients with advanced non-small cell lung cancer, improve patient immunity, improve the quality of survival, and reduce the toxic side effects of chemotherapy drugs and high safety, which is clinically recommended as one of the comprehensive treatment means of non-small cell lung cancer. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
